Samuel McGrath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Samuel McGrath has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Bashir Alaour
King’s College London
2 shared publicationsMichael Marber
King’s College London
2 shared publications- Aaron Goldberg
Stoke Mandeville Hospital, Aylesbury HP21 8AL, UK
1 shared publication - Abdul Mozid
Department of Cardiology, Leeds General Infirmary, Leeds, UK
1 shared publication - Ahmed Elamin
Liverpool Heart and Chest Hospital, United Kingdom (A.E., Z.Y., C.A.).
1 shared publication - Ajay M. Shah
King's College London
1 shared publication
Latest Publications
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (4) , e015918
Prospective Validation of the MIRACLE 2 Score for Early Neurological Stratification After Out-of-Hospital Cardiac-Arrest: The GLOBAL-MIRACLE Registry
BACKGROUND: The purpose of this study was to prospectively validate the MIRACLE 2 score in the GLOBAL-MIRACLE registry, a multicenter, international, prospective registry of patients admitted with resuscitated out-of-hospital cardiac arrest of presumed cardiac cause. METHODS: From January 1, 2022 to May 31, 2023, 770 patients were recruited from 11 centers across 5 countries. The primary end point was poor neurological outcome (Cerebral Performance Category 3–5) at hospital discharge. Model discrimination was assessed by the area under the receiver operating characteristic curve. We compared the discriminatory performance of the MIRACLE 2 score against Cardiac Arrest Hospital Prognosis, out-of-hospital cardiac arrest, Target Temperature Management, NULL-PLEASE, C-GRAPH, and rCAST. RESULTS: The primary end point occurred in 395 (51.2%) patients. The MIRACLE 2 score had an area under the curve of 0.861 (95% CI, 0.835–0.887). A MIRACLE 2 score ≤2 had a negative predictive value of 87.8%, while a score of ≥7 had a positive predictive value of 98.3%. The MIRACLE 2 score had equal performance to the TTM risk tool ( P =0.12) but better discriminatory performance than other risk tools ( P 2 score showed good performance in those with ST-segment–elevation myocardial infarction (0.851 [95% CI, 0.816–0.886]) and without ST-segment–elevation myocardial infarction (0.873 [95% CI, 0.834–0.912]) and in those with cardiogenic shock (0.832 [95% CI, 0.789–0.875]) and without cardiogenic shock (0.853 [95% CI, 0.810–0.895]). CONCLUSIONS: The MIRACLE 2 score is a practical risk tool that shows excellent discrimination performance for poor neurological outcome after presumed cardiac cause out-of-hospital cardiac arrest, including based on hemodynamic status and admission 12-lead ECG. Early stratification of out-of-hospital cardiac arrest patients using the MIRACLE 2 score should be evaluated in future randomized controlled trials.
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (4) , e015918
Prospective Validation of the MIRACLE 2 Score for Early Neurological Stratification After Out-of-Hospital Cardiac-Arrest: The GLOBAL-MIRACLE Registry
BACKGROUND: The purpose of this study was to prospectively validate the MIRACLE 2 score in the GLOBAL-MIRACLE registry, a multicenter, international, prospective registry of patients admitted with resuscitated out-of-hospital cardiac arrest of presumed cardiac cause. METHODS: From January 1, 2022 to May 31, 2023, 770 patients were recruited from 11 centers across 5 countries. The primary end point was poor neurological outcome (Cerebral Performance Category 3–5) at hospital discharge. Model discrimination was assessed by the area under the receiver operating characteristic curve. We compared the discriminatory performance of the MIRACLE 2 score against Cardiac Arrest Hospital Prognosis, out-of-hospital cardiac arrest, Target Temperature Management, NULL-PLEASE, C-GRAPH, and rCAST. RESULTS: The primary end point occurred in 395 (51.2%) patients. The MIRACLE 2 score had an area under the curve of 0.861 (95% CI, 0.835–0.887). A MIRACLE 2 score ≤2 had a negative predictive value of 87.8%, while a score of ≥7 had a positive predictive value of 98.3%. The MIRACLE 2 score had equal performance to the TTM risk tool ( P =0.12) but better discriminatory performance than other risk tools ( P 2 score showed good performance in those with ST-segment–elevation myocardial infarction (0.851 [95% CI, 0.816–0.886]) and without ST-segment–elevation myocardial infarction (0.873 [95% CI, 0.834–0.912]) and in those with cardiogenic shock (0.832 [95% CI, 0.789–0.875]) and without cardiogenic shock (0.853 [95% CI, 0.810–0.895]). CONCLUSIONS: The MIRACLE 2 score is a practical risk tool that shows excellent discrimination performance for poor neurological outcome after presumed cardiac cause out-of-hospital cardiac arrest, including based on hemodynamic status and admission 12-lead ECG. Early stratification of out-of-hospital cardiac arrest patients using the MIRACLE 2 score should be evaluated in future randomized controlled trials.
- Open Access
- 14 November 2025
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 23 (12) , 855-866
Myocardial injury biomarkers and their assays: advances, insights, and future directions
Cardiac Troponin (cTn) is fundamental to the diagnosis of myocardial injury. High sensitivity cTn assays have transformed acute cardiac care by shifting the focus toward rapid rule-out of myocardial infarction, allowing the early identification and safe discharge of low-risk patients. However, cTn proteins and their assays have limitations. The review summarizes cTn as a biomarker of myocardial injury, high-sensitivity cTn assay performance, and their combined impact on chest pain pathways. It explores Cardiac Myosin-Binding Protein C (cMyC) and discusses the evidence behind its use as an alternative biomarker. Studies available on Pubmed were analyzed using keywords cTn, cMyC, myocardial infarction, triage, chest pain and assay. The second half of this review explores the proteolysis of both these biomarkers, and how this information could be used in clinical practice. Both hs-cTn and hs-cMyC assays have shown equivalent diagnostic performance in the rule-out of myocardial infarction. Unfortunately, both are also plagued by the similar liabilities: decreased specificity for Type 1 AMI, and an inability to distinguish between types of myocardial injury. Proteolysis of each biomarker differs according to underlying pathology. Novel assays that quantify distinct forms could enhance patient triage.
- 14 November 2025
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 23 (12) , 855-866
Open AccessMyocardial injury biomarkers and their assays: advances, insights, and future directions
Cardiac Troponin (cTn) is fundamental to the diagnosis of myocardial injury. High sensitivity cTn assays have transformed acute cardiac care by shifting the focus toward rapid rule-out of myocardial infarction, allowing the early identification and safe discharge of low-risk patients. However, cTn proteins and their assays have limitations. The review summarizes cTn as a biomarker of myocardial injury, high-sensitivity cTn assay performance, and their combined impact on chest pain pathways. It explores Cardiac Myosin-Binding Protein C (cMyC) and discusses the evidence behind its use as an alternative biomarker. Studies available on Pubmed were analyzed using keywords cTn, cMyC, myocardial infarction, triage, chest pain and assay. The second half of this review explores the proteolysis of both these biomarkers, and how this information could be used in clinical practice. Both hs-cTn and hs-cMyC assays have shown equivalent diagnostic performance in the rule-out of myocardial infarction. Unfortunately, both are also plagued by the similar liabilities: decreased specificity for Type 1 AMI, and an inability to distinguish between types of myocardial injury. Proteolysis of each biomarker differs according to underlying pathology. Novel assays that quantify distinct forms could enhance patient triage.
- Open Access
- 23 July 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (20) , 104181
The Secret Life of a Lost Guidewire
- 23 July 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (20) , 104181
Open AccessThe Secret Life of a Lost Guidewire
- Open Access
- 10 June 2025
- Published by Radcliffe Medical Media Ltd in Interventional Cardiology: Reviews, Research, Resources
- Vol. 20
Evaluation of the UK Intervention Subspecialty Programme: The Trainees’ Experience
Background: Interventional cardiology (IC) is a competitive and oversubscribed subspecialty. The UK cardiology programme is currently in a state of transition of curricula, and concerns have arisen about the impact of this change on the standard of training. This study aimed to provide a snapshot of UK IC training at present. Methods: A 68-question survey was disseminated through the British Cardiovascular Interventional Society mailing list in November 2023 to all UK intervention trainees across both curricula. Questions included procedural numbers, exposure to adjunct techniques and confidence in the transition to consultancy. Results: The survey was completed by 60 participants, providing a response rate of 38% for training grades. A total of 87% of participants were men, and 78% remained on the 2010 curriculum. For the 2010 curriculum trainees, the median number of first-operator percutaneous coronary intervention was 101–200 in their first year. Confidence levels were higher for radial (98%) than femoral (62%) access. A total of 83% felt comfortable or confident using intravascular lithotripsy (83%) compared with 23% for rotational atherectomy. Comfort was higher with intravascular ultrasound (82%) compared with optical coherence tomography (53%). Half felt unprepared for consultancy, citing insufficient procedural experience. To address this, 65% plan to extend training with a fellowship year. Overall, 72% rated the programme as excellent or good, and 10% as poor. Conclusion: While many trainees report a positive experience with UK IC training, several areas need improvement, including procedural volume and requirement for extended training. Moving forward, it will be crucial to monitor the impact of the 2022 curriculum on IC training.
- 10 June 2025
- Published by Radcliffe Medical Media Ltd in Interventional Cardiology: Reviews, Research, Resources
- Vol. 20
Open AccessEvaluation of the UK Intervention Subspecialty Programme: The Trainees’ Experience
Background: Interventional cardiology (IC) is a competitive and oversubscribed subspecialty. The UK cardiology programme is currently in a state of transition of curricula, and concerns have arisen about the impact of this change on the standard of training. This study aimed to provide a snapshot of UK IC training at present. Methods: A 68-question survey was disseminated through the British Cardiovascular Interventional Society mailing list in November 2023 to all UK intervention trainees across both curricula. Questions included procedural numbers, exposure to adjunct techniques and confidence in the transition to consultancy. Results: The survey was completed by 60 participants, providing a response rate of 38% for training grades. A total of 87% of participants were men, and 78% remained on the 2010 curriculum. For the 2010 curriculum trainees, the median number of first-operator percutaneous coronary intervention was 101–200 in their first year. Confidence levels were higher for radial (98%) than femoral (62%) access. A total of 83% felt comfortable or confident using intravascular lithotripsy (83%) compared with 23% for rotational atherectomy. Comfort was higher with intravascular ultrasound (82%) compared with optical coherence tomography (53%). Half felt unprepared for consultancy, citing insufficient procedural experience. To address this, 65% plan to extend training with a fellowship year. Overall, 72% rated the programme as excellent or good, and 10% as poor. Conclusion: While many trainees report a positive experience with UK IC training, several areas need improvement, including procedural volume and requirement for extended training. Moving forward, it will be crucial to monitor the impact of the 2022 curriculum on IC training.
- Open Access
- 25 April 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (5) , 101695
Cardiac Troponin
- 25 April 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (5) , 101695
Open AccessCardiac Troponin
- Open Access
- 12 December 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (24) , 7570
How Close Are We to Patient-Side Troponin Testing?
Laboratory-based high-sensitivity cardiac troponin testing has been the pillar for emergency stratification of suspected acute coronary syndrome for well over a decade. Point-of-care troponin assays achieving the requisite analytical sensitivity have recently been developed and could accelerate such assessment. This review summarises the latest assays and describes their potential diverse clinical utility in the emergency department, community healthcare, pre-hospital, and other hospital settings. It outlines the current clinical data but also highlights the evidence gap, particularly the need for clinical trials using whole blood, that must be addressed for safe and successful implementation of point-of-care troponin analysis into daily practice. Additionally, how point-of-care troponin testing can be coupled with advances in biosensor technology, cardiovascular screening, and triage algorithms is discussed.
- 12 December 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (24) , 7570
Open AccessHow Close Are We to Patient-Side Troponin Testing?
Laboratory-based high-sensitivity cardiac troponin testing has been the pillar for emergency stratification of suspected acute coronary syndrome for well over a decade. Point-of-care troponin assays achieving the requisite analytical sensitivity have recently been developed and could accelerate such assessment. This review summarises the latest assays and describes their potential diverse clinical utility in the emergency department, community healthcare, pre-hospital, and other hospital settings. It outlines the current clinical data but also highlights the evidence gap, particularly the need for clinical trials using whole blood, that must be addressed for safe and successful implementation of point-of-care troponin analysis into daily practice. Additionally, how point-of-care troponin testing can be coupled with advances in biosensor technology, cardiovascular screening, and triage algorithms is discussed.